Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Lung Cancer

Free Subscription Articles published in J Clin Invest Retrieve available abstracts of 41 articles: HTML format

Single Articles

May 2026
1. XING W, Zhou Y, Haedicke K, Wang C, et al
   Label-free streamlined photoacoustic image guidance facilitates NIR-II photoablation in models of melanoma lung metastases.
   J Clin Invest. 2026;136:e196095.
   PubMed     Abstract available
   
   
   April 2026
2. ZHAO Y, Zhou Y, Pan L, Tian GG, et al
   Therapy-induced cholesterol biosynthesis drives lung cancer dormancy and drug resistance.
   J Clin Invest. 2026;136:e191735.
   PubMed     Abstract available
   
   
   March 2026
3. ZHUANG WT, Pang LL, Hu LY, Liao J, et al
   EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-gamma.
   J Clin Invest. 2026;136:e194377.
   PubMed     Abstract available
   
   
   February 2026
4. BURNS TF, Dacic S, Chakka A, Miller E, et al
   MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype.
   J Clin Invest. 2025;136:e194708.
   PubMed     Abstract available
   
   
   
5. LI H, De Santis MC, Tucci FA, Tosoni D, et al
   SH3BP5L triggers the RAB11A-regulated integrin recycling network implicated in breast cancer metastasis.
   J Clin Invest. 2026;136:e192705.
   PubMed     Abstract available
   
   
   
6. GHOSH M, Wu C, Kumar A, Nilsson M, et al
   Osimertinib activates a TGF-beta2-dependent secretory program that drives lung adenocarcinoma progression.
   J Clin Invest. 2025;136:e198418.
   PubMed     Abstract available
   
   
   January 2026
7. KENT JR, Abbott KL, Nordgren R, Deik A, et al
   Intraoperative arteriovenous patient sampling to assess in situ non-small cell lung cancer metabolism.
   J Clin Invest. 2026 Jan 27:e198821. doi: 10.1172/JCI198821.
   PubMed    
   
   
   December 2025
8. QIU Z, Song NJ, Li A, Singh D, et al
   PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation.
   J Clin Invest. 2025 Dec 18:e193354. doi: 10.1172/JCI193354.
   PubMed     Abstract available
   
   
   November 2025
9. HAJI S, Ogawa Y
   TET3-overexpressing macrophages are a unifying pathogenic feature with therapeutic potential in chronic inflammatory diseases.
   J Clin Invest. 2025;135:e198802.
   PubMed     Abstract available
   
   
   
10. LIU B, Dai Y, Wang Z, Song J, et al
    TET3 is a common epigenetic immunomodulator of pathogenic macrophages.
    J Clin Invest. 2025;135:e194879.
    PubMed     Abstract available
    
    
    October 2025
11. DRAGONI F, Sop J, Gurumurthy I, Beckey TP, et al
    Selective targeting of HIV infected clones by cognate peptide stimulation and antiproliferative drugs.
    J Clin Invest. 2025 Oct 21:e197266. doi: 10.1172/JCI197266.
    PubMed     Abstract available
    
    
    
12. ZENG C, Wang X, Zhong J, Zhang Y, et al
    PIM3-mediated phosphorylation stabilizes myeloid leukemia factor 2 to promote metastasis in osteosarcoma.
    J Clin Invest. 2025;135:e191040.
    PubMed     Abstract available
    
    
    
13. RAINES B, Tseng-Rogenski S, Dowdican AC, Peris I, et al
    A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer.
    J Clin Invest. 2025 Oct 14:e193790. doi: 10.1172/JCI193790.
    PubMed     Abstract available
    
    
    September 2025
14. KRATZMEIER C, Taheri M, Mei Z, Lim I, et al
    Lung adenocarcinoma-derived IFN-gamma promotes growth by modulating CD8+ T cell production of CCR5 chemokines.
    J Clin Invest. 2025;135:e191070.
    PubMed     Abstract available
    
    
    August 2025
15. XIONG T, Wang G, Yu P, Li Z, et al
    CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors.
    J Clin Invest. 2025;135:e189920.
    PubMed     Abstract available
    
    
    July 2025
16. KIM YS, Nabet BY, Cortez BN, Sun NY, et al
    NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING.
    J Clin Invest. 2025 Jul 8:e185423. doi: 10.1172/JCI185423.
    PubMed     Abstract available
    
    
    June 2025
17. DESAI SS, Salahuddin S, Yusuf R, Ranjan K, et al
    Tumor microenvironment of non-small cell lung cancer impairs immune cell function among people with HIV.
    J Clin Invest. 2025 Jun 3:e177310. doi: 10.1172/JCI177310.
    PubMed     Abstract available
    
    
    
18. LEE S, Park J, Cho S, Kim EJ, et al
    Hyaluronan network remodeling by ZEB1 and ITIH2 enhances the motility and invasiveness of cancer cells.
    J Clin Invest. 2025;135:e180570.
    PubMed     Abstract available
    
    
    May 2025
19. APPADURAI MI, Chaudhary S, Shah A, Natarajan G, et al
    ST6GalNAc-I regulates tumor cell sialylation via NECTIN2/MUC5AC-mediated immunosuppression and angiogenesis in non-small cell lung cancer.
    J Clin Invest. 2025;135:e186863.
    PubMed     Abstract available
    
    
    April 2025
20. O'KEEFE S, Wang Q
    ACAT1 regulates tertiary lymphoid structures: A target for enhancing immunotherapy in non-small cell lung cancer.
    J Clin Invest. 2025;135:e191094.
    PubMed     Abstract available
    
    
    
21. WANG S, Guo H, Fukushima R, Terajima M, et al
    Lysyl hydroxylase 2 glucosylates collagen VI to drive lung cancer progression.
    J Clin Invest. 2025;135:e189197.
    PubMed     Abstract available
    
    
    
22. JIAO M, Guo Y, Zhang H, Wen H, et al
    ACAT1 regulates tertiary lymphoid structures and correlates with immunotherapy response in non-small cell lung cancer.
    J Clin Invest. 2025;135:e181517.
    PubMed     Abstract available
    
    
    March 2025
23. SHEN S, Zhang Q, Wang Y, Chen H, et al
    Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS-mutant cancer models.
    J Clin Invest. 2025;135:e185278.
    PubMed     Abstract available
    
    
    February 2025
24. YU F, Zheng S, Yu C, Gao S, et al
    KRAS Mutants Confer Platinum Resistance by Regulating ALKBH5 Post-translational Modifications in Lung Cancer.
    J Clin Invest. 2025 Feb 4:e185149. doi: 10.1172/JCI185149.
    PubMed     Abstract available
    
    
    December 2024
25. LI D, Geng K, Hao Y, Gu J, et al
    Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models.
    J Clin Invest. 2024 Dec 24:e174249. doi: 10.1172/JCI174249.
    PubMed     Abstract available
    
    
    October 2024
26. HUANG Q, Tian N, Zhang J, Song S, et al
    Nonclassical action of Ku70 promotes Treg-suppressive function through a FOXP3-dependent mechanism in lung adenocarcinoma.
    J Clin Invest. 2024;134:e178079.
    PubMed     Abstract available
    
    
    September 2024
27. REEVES MQ
    Mapping the transcriptional evolution of human metastatic breast cancer.
    J Clin Invest. 2024;134:e183971.
    PubMed     Abstract available
    
    
    June 2024
28. PARDO L, Norman JC
    Targeting the secretory program of 3q-amplified lung cancers.
    J Clin Invest. 2024;134:e181798.
    PubMed     Abstract available
    
    
    May 2024
29. MILLS GB, Labrie M
    Enhancing anticancer activity of macrophages through rational drug combinations.
    J Clin Invest. 2024;134:e180512.
    PubMed     Abstract available
    
    
    April 2024
30. HAYASHI H, Chamoto K, Hatae R, Kurosaki T, et al
    Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
    J Clin Invest. 2024;134:e168318.
    PubMed     Abstract available
    
    
    
31. TAN AC, Cook SL, Khasraw M
    Soluble immune-checkpoint factors: a potential immunotherapy biomarker.
    J Clin Invest. 2024;134:e179352.
    PubMed     Abstract available
    
    
    March 2024
32. VACCARO K, Allen J, Whitfield TW, Maoz A, et al
    Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.
    J Clin Invest. 2024;134:e169315.
    PubMed     Abstract available
    
    
    
33. CHEN Z, Vallega KA, Wang D, Quan Z, et al
    DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    J Clin Invest. 2024 Mar 7:e172716. doi: 10.1172/JCI172716.
    PubMed     Abstract available
    
    
    January 2024
34. PEYVANDI S, Bulliard M, Yilmaz A, Kauzlaric A, et al
    Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via OSM/IL6-JAK-induced cancer cell plasticity.
    J Clin Invest. 2024 Jan 18:e166847. doi: 10.1172/JCI166847.
    PubMed     Abstract available
    
    
    
35. GHANBAR MI, Suresh K
    Pulmonary toxicity of immune checkpoint immunotherapy.
    J Clin Invest. 2024;134:e170503.
    PubMed     Abstract available
    
    
    December 2023
36. JING N, Zhang K, Chen X, Liu K, et al
    ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.
    J Clin Invest. 2023;133:e168670.
    PubMed     Abstract available
    
    
    
37. WANG S, Iyer R, Han X, Wei J, et al
    CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion.
    J Clin Invest. 2023;133:e167728.
    PubMed     Abstract available
    
    
    November 2023
38. MAKINEN N, Meyerson M
    Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
    J Clin Invest. 2023;133:e174171.
    PubMed     Abstract available
    
    
    October 2023
39. LIU S, Saunders M, Mak TW
    Chemical carcinogens: implications for cancer treatment.
    J Clin Invest. 2023;133:e174319.
    PubMed     Abstract available
    
    
    
40. HUANG M, Xia Y, Li K, Shao F, et al
    Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment.
    J Clin Invest. 2023;133:e166494.
    PubMed     Abstract available
    
    
    
41. WANG T, Dong Y, Huang Z, Zhang G, et al
    Antioxidants stimulate BACH1-dependent tumor angiogenesis.
    J Clin Invest. 2023;133:e169671.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum